Stroke, Acute Clinical Trial
— galopOfficial title:
Robot Assisted Therapy for Acute Stroke Patients: a Comparative Study of GangTrainer GT I, Lokomat System and Conventional Physiotherapy
The GangTrainer GT I and the Lokomat have proven their effectiveness on stroke Patients, but a comparison on the same controlled study population has not been made so far. Aim of the study will not only be to establish which device will work better on acute, non ambulatory stroke Patients in terms of regain of gait ability and motor function, but also clinical matters, like the efficacy of the treatment period. As a result of the trial it should be highlighted which kind of therapy has to be suggested for Patients comparable to the study population. A significant better outcome of one device in regard to the other will suggest to use one device more than the other for future treatments.
Status | Suspended |
Enrollment | 120 |
Est. completion date | February 2016 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 79 Years |
Eligibility |
Inclusion Criteria: - First supratentorial stroke (ischaemic, haemorrhagic or ICH) resulting in a hemiparesis - Interval from stroke 3 - 12 weeks - Non ambulatory (FAC < 3) - Free sitting on bedside for 1 minute, both feet on the floor, ev. holding on bedside by hands - Barthel Index 25 - 65 Exclusion Criteria: - Unstable cardiovascular system (in case of doubt, only after approval by a internist) - Manifested heart diseases like labile compensated cardiac insufficiency (NYHA III), angina pectoris, myocardial infarction 120 days before study onset, cardiomyopathy, severe cardiac arrhythmia - Severe joint misalignment (severe constriction of movement for hip, knee and/or ankle: more than 20° fixed hip and knee extension deficit, or more than 20° fixed plantar flexion of the ankle - Severe cognitive dysfunction, which does not allow for comprehension of the aims of this study - Severe neurological or orthopaedic diseases (like polio, Parkinson´s disease), which massively affect the mobility - Deep vein thrombosis - Severe osteoporosis - Malignant tumour diseases |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Austria | Hochzirl Hospital | Hochzirl | Tirol |
Italy | Claudiana Landesfachhochschule | Bozen | Südtirol |
Italy | Krankenhaus Bozen | Bozen | Südtirol |
Italy | Privatklinik Villa Melitta | Bozen | Südtirol |
Italy | Krankenhaus Brixen | Brixen | Südtirol |
Italy | Krankenhaus Bruneck | Bruneck | Südtirol |
Italy | Krankenhaus Meran | Meran | Südtirol |
Lead Sponsor | Collaborator |
---|---|
Research Department for Neurorehabilitation South Tyrol | Claudiana Landesfachhochschule, Hochzirl Hospital, Krankenhaus Bozen, Krankenhaus Brixen, Krankenhaus Bruneck, Krankenhaus Meran, Privatklinik Villa Melitta |
Austria, Italy,
Baer HR, Wolf SL. Modified emory functional ambulation profile: an outcome measure for the rehabilitation of poststroke gait dysfunction. Stroke. 2001 Apr;32(4):973-9. — View Citation
Barbeau H, Visintin M. Optimal outcomes obtained with body-weight support combined with treadmill training in stroke subjects. Arch Phys Med Rehabil. 2003 Oct;84(10):1458-65. — View Citation
Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987 Feb;67(2):206-7. — View Citation
Collen FM, Wade DT, Robb GF, Bradshaw CM. The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment. Int Disabil Stud. 1991 Apr-Jun;13(2):50-4. — View Citation
Hidler J, Nichols D, Pelliccio M, Brady K, Campbell DD, Kahn JH, Hornby TG. Multicenter randomized clinical trial evaluating the effectiveness of the Lokomat in subacute stroke. Neurorehabil Neural Repair. 2009 Jan;23(1):5-13. doi: 10.1177/1545968308326632. — View Citation
Holden MK, Gill KM, Magliozzi MR, Nathan J, Piehl-Baker L. Clinical gait assessment in the neurologically impaired. Reliability and meaningfulness. Phys Ther. 1984 Jan;64(1):35-40. — View Citation
Kolominsky-Rabas PL, Heuschmann PU. [Incidence, etiology and long-term prognosis of stroke]. Fortschr Neurol Psychiatr. 2002 Dec;70(12):657-62. German. — View Citation
Lord SE, Halligan PW, Wade DT. Visual gait analysis: the development of a clinical assessment and scale. Clin Rehabil. 1998 Apr;12(2):107-19. — View Citation
MAHONEY FI, BARTHEL DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J. 1965 Feb;14:61-5. — View Citation
Pohl M, Werner C, Holzgraefe M, Kroczek G, Mehrholz J, Wingendorf I, Hoölig G, Koch R, Hesse S. Repetitive locomotor training and physiotherapy improve walking and basic activities of daily living after stroke: a single-blind, randomized multicentre trial (DEutsche GAngtrainerStudie, DEGAS). Clin Rehabil. 2007 Jan;21(1):17-27. — View Citation
Regnaux JP, Saremi K, Marehbian J, Bussel B, Dobkin BH. An accelerometry-based comparison of 2 robotic assistive devices for treadmill training of gait. Neurorehabil Neural Repair. 2008 Jul-Aug;22(4):348-54. Epub 2007 Dec 11. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional Ambulation Category (FAC) | after 8 weeks | No | |
Secondary | Barthel Index (BI) | at week 1 | No | |
Secondary | Barthel Index (BI) | after 4 weeks | No | |
Secondary | Barthel Index (BI) | after 8 weeks | No | |
Secondary | Barthel Index (BI) | after 24 weeks | No | |
Secondary | Rivermead Mobility Index (RMI) | at week 1 | No | |
Secondary | Rivermead Mobility Index (RMI) | after 4 weeks | No | |
Secondary | Rivermead Mobility Index (RMI) | after 8 weeks | No | |
Secondary | Rivermead Mobility Index (RMI) | after 24 weeks | No | |
Secondary | 10 metres Walking Test | at week 1 | No | |
Secondary | 10 metres Walking Test | after 4 weeks | No | |
Secondary | 10 metres Walking Test | after 8 weeks | No | |
Secondary | 10 metres Walking Test | after 24 weeks | No | |
Secondary | 6 Minutes Walking Test on the Floor | at week 1 | No | |
Secondary | 6 Minutes Walking Test on the Floor | after 4 weeks | No | |
Secondary | 6 Minutes Walking Test on the Floor | after 8 weeks | No | |
Secondary | 6 Minutes Walking Test on the Floor | after 24 weeks | No | |
Secondary | 6 Minutes Walking Test on the Treadmill with Body Weight Support | at week 1 | No | |
Secondary | 6 Minutes Walking Test on the Treadmill with Body Weight Support | after 4 weeks | No | |
Secondary | 6 Minutes Walking Test on the Treadmill with Body Weight Support | after 8 weeks | No | |
Secondary | 6 Minutes Walking Test on the Treadmill with Body Weight Support | after 24 weeks | No | |
Secondary | Medical Research Council (MRC) | at week 1 | Yes | |
Secondary | Medical Research Council (MRC) | after 4 weeks | No | |
Secondary | Medical Research Council (MRC) | after 8 weeks | No | |
Secondary | Medical Research Council (MRC) | after 24 weeks | No | |
Secondary | Modified Ashworth Scale (mAS) | at week 1 | No | |
Secondary | Modified Ashworth Scale (mAS) | after 4 weeks | No | |
Secondary | Modified Ashworth Scale (mAS) | after 8 weeks | No | |
Secondary | Modified Ashworth Scale (mAS) | after 24 weeks | No | |
Secondary | Rivermead Visual Gait Assessment (RVGA) | at week 1 | No | |
Secondary | Rivermead Visual Gait Assessment (RVGA) | after 8 weeks | No | |
Secondary | Rivermead Visual Gait Assessment (RVGA) | after 24 weeks | Yes | |
Secondary | EuroQol 5 Dimensions (EQ-5D) | at week 1 | No | |
Secondary | EuroQol 5 Dimensions (EQ-5D) | after 8 weeks | No | |
Secondary | EuroQol 5 Dimensions (EQ-5D) | after 24 weeks | No | |
Secondary | modified emory Functional Ambulation Profile (meFAP) | at week 1 | No | |
Secondary | modified emory Functional Ambulation Profile (meFAP) | after 4 weeks | Yes | |
Secondary | modified emory Functional Ambulation Profile (meFAP) | after 8 weeks | No | |
Secondary | modified emory Functional Ambulation Profile (meFAP) | after 24 weeks | No | |
Secondary | Functional Ambulation Category (FAC) | at week 1 | No | |
Secondary | Functional Ambulation Category (FAC) | after 4 weeks | No | |
Secondary | Functional Ambulation Category (FAC) | after 24 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05378035 -
DOAC in Chinese Patients With Atrial Fibrillation
|
||
Completed |
NCT03679637 -
Tablet-based Aphasia Therapy in the Acute Phase After Stroke
|
N/A | |
Completed |
NCT03574038 -
Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke
|
N/A | |
Completed |
NCT03633422 -
Evaluation of Stroke Patient Screening
|
||
Completed |
NCT04088578 -
VNS-supplemented Motor Retraining After Stroke
|
N/A | |
Withdrawn |
NCT04991038 -
Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients
|
N/A | |
Not yet recruiting |
NCT05534360 -
Tenecteplase Treatment in Ischemic Stroke Registry
|
||
Withdrawn |
NCT05786170 -
ERILs Und SNILs Unter SOC
|
N/A | |
Not yet recruiting |
NCT04105322 -
Effects of Kinesio Taping on Balance and Functional Performance in Stroke Patients
|
N/A | |
Recruiting |
NCT03132558 -
Contrast Induced Acute Kidney in Patients With Acute Stroke
|
N/A | |
Completed |
NCT02893631 -
Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
|
||
Active, not recruiting |
NCT02274727 -
Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
|
||
Completed |
NCT02225730 -
Imaging Collaterals in Acute Stroke (iCAS)
|
||
Terminated |
NCT01705353 -
The Role of HMGB-1 in Chronic Stroke
|
N/A | |
Active, not recruiting |
NCT01581502 -
SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)
|
N/A | |
Completed |
NCT01182818 -
Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease
|
N/A | |
Completed |
NCT00761982 -
Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment.
|
Phase 1/Phase 2 | |
Completed |
NCT00535197 -
Autologous Bone Marrow Stem Cells in Ischemic Stroke.
|
Phase 1/Phase 2 | |
Terminated |
NCT00132509 -
FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke
|
Phase 2 | |
Recruiting |
NCT05760326 -
Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients
|